Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
(R)-4-Methyloxazolidin-2-one → (R)-3-{4-[4-(3,5-dimethylpyrazin-2-yl)piperazine-1-carbonyl]-3-fluorophenyl}-4-methyloxazolidin-2-one
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | (R)-4-Methyloxazolidin-2-one | HCID 2734858 | — |
| 반응물 | (4-Bromo-2-fluorophenyl)[4-(3,5-dimethylpyrazin-2-yl)piperazin-1-yl]methanone | HCID 58484696 | — |
| 생성물 | (R)-3-{4-[4-(3,5-dimethylpyrazin-2-yl)piperazine-1-carbonyl]-3-fluorophenyl}-4-methyloxazolidin-2-one | HCID 58484514 | 82.2% |
반응 단계
By reaction and treatment in the same manner as in Example 1 and using (4-bromo-2-fluorophenyl)[4-(3,5-dimethylpyrazin-2-yl)piperazin-1-yl]methanone (611 mg) described in Preparation Example 105 and (R)-4-methyloxazolidin-2-one (212 mg) described in Preparation Example 25, the title compound (528 mg) was obtained.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08354401B2 |
| 출처 데이터셋 | uspto-grants-2013_01 |
| ORD ID | ord-d95294ffdef7408591894cb27f257f1a |
| 출처 메모 | uspto-grants-2013_01 |